AstraZeneca (AZNCF, $99.60) vaccine linked to deadly blood clots in rare instances
The coronavirus vaccine developed by AstraZeneca PLC has been linked to an autoimmune reaction that can lead to deadly blood clots in rare instances, according to a study by researchers in Norway and Germany.
According to the researchers in Norway and Germany, the vaccine could trigger an autoimmune reaction that causes blood to clot in the brain, the Wall Street Journal reported. The research could lead to a possible treatment to prevent the problem, the paper said. Symptoms such as dizziness and blurred vision occur several days after the vaccine is administered. But the condition can be detected by a simple blood test and easily treated in a hospital, according to the report.
Last week, there was a brief halting of the AstraZeneca vaccine rollout in Europe after several people who received the vaccine died. But later in the week, EU regulators allowed the use of the vaccine, after assessing that benefits far outweighed the risks of the vaccine.
Momentum Indicator for AZNCF turns positive, indicating new upward trend
AZNCF saw its Momentum Indicator move above the 0 level on November 06, 2025. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 115 similar instances where the indicator turned positive. In of the 115 cases, the stock moved higher in the following days. The odds of a move higher are at .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for AZNCF just turned positive on November 10, 2025. Looking at past instances where AZNCF's MACD turned positive, the stock continued to rise in of 51 cases over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where AZNCF advanced for three days, in of 249 cases, the price rose further within the following month. The odds of a continued upward trend are .
Bearish Trend Analysis
The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 14 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
AZNCF broke above its upper Bollinger Band on November 25, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for AZNCF entered a downward trend on November 10, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.369) is normal, around the industry mean (9.017). P/E Ratio (31.312) is within average values for comparable stocks, (24.286). Projected Growth (PEG Ratio) (1.085) is also within normal values, averaging (2.105). Dividend Yield (0.017) settles around the average of (0.026) among similar stocks. P/S Ratio (5.066) is also within normal values, averaging (3.698).
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 73, placing this stock better than average.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. AZNCF’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry PharmaceuticalsMajor
Advertisement